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Abstract 
Background: Despite the efficacy of decitabine treatment in myelodysplastic syndrome (MDS), no definite predictor 
of response is known. In this study, we investigated whether the expression levels of human equilibrative nucleoside 
transporter 1 (hENT1), hENT2, deoxycytidine kinase (DCK) and cytidine deaminase (CDA) genes could predict response 
to decitabine in MDS.
Methods: We performed quantitative real-time PCR in marrow mononuclear cells to examine the expression of 
hENT1, hENT2, DCK, and CDA prior to therapy in 98 MDS patients initially treated with decitabine. Response and overall 
survival of patients treated with decitabine were analyzed according to gene expression levels. HENT1 knockdown 
was performed by shRNA in the SKM-1 cell line, and the effect of this on the demethylation ability of decitabine on 
long interspersed nucleotide element 1 (LINE1) was investigated.
Results: Patients responding to decitabine presented with significantly higher hENT1 expression levels than non-
responders (p = 0.004). Overall response, complete response, and cytogenetic complete response rate in patients 
with high hENT1 expression (79.4, 41.3, and 43.8 %) were significantly higher than those in patients with low hENT1 
expression (48.6, 20.0, and 5.9 %, respectively) (p = 0.004, 0.033, and 0.006, respectively). In higher-risk MDS, patients 
with high hENT1 expression showed prolonged survival compared with those with low hENT1 expression (22.0 vs 
14.0 months; p = 0.027). However, the expression levels of hENT2, DCK, and CDA did not affect response rate. Knock-
down of hENT1 in SKM-1 cells weakened the demethylation effect on LINE1 induced by decitabine.
Conclusions: High expression of hENT1 appears to predict a good response to decitabine and a prolonged survival 
in higher-risk MDS patients treated with decitabine. HENT1 expression knockdown weakens the demethylation effect 
of decitabine.
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Background
Myelodysplastic syndromes (MDS) are recognized 
as among the most common hematological neo-
plasms [1], comprising a heterogeneous group of clonal 
hematopoietic stem/progenitor cell disorders char-
acterized by ineffective hematopoiesis, dysplastic cell 
morphology, and the potential for clonal evolution [2]. 
Approximately 50–60  % MDS patients have abnormal 
karyotypes, frequently with 5q-, +8, −7(q) or 20q- [1]. 
Decitabine is one of the drugs approved for treatment 
of MDS, and low-dose decitabine has been proven to be 
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of patients do not respond to this treatment initially [4, 
5], and there are almost no effective factors predicting 
which patients will respond to decitabine before starting 
the therapy.
It is likely that genetic variability of key enzymes in 
decitabine transport and metabolism may have an impact 
on the treatment response of decitabine. Thus, the 
expression levels of genes related to decitabine transport 
[including human equilibrative nucleoside transporter 1 
(hENT1) and hENT2], and metabolism [including deox-
ycytidine kinase (DCK) and cytidine deaminase (CDA)] 
may influence the therapeutic effect of the drug.
Because the biochemical targets of decitabine are 
intracellular, the mandatory first step in the production 
of cytotoxicity is permeation across the cell membrane. 
Decitabine and physiologic nucleosides are hydrophilic, 
and diffusion through the cell membrane lipid layer is 
slow. Therefore, efficient cellular uptake requires the 
presence of specialized integral membrane nucleoside 
transporter proteins [6]. Two general processes of nucle-
oside transport have been identified: the equilibrative 
bi-directional facilitators (hENT1 and 2) and the con-
centrative sodium/nucleoside symporters hCNT1 and 3. 
The major routes for transporting decitabine are hENT1 
and hENT2, and, to a lesser extent, hCNT1 and hCNT3 
[6]. When transporting into the cell, decitabine is phos-
phorylated into monophosphorylated derivative 5-azad-
CMPby deoxycytidine (DCK). Then, 5-aza-dCMP is 
phosphorylated to 5-aza-dCTP, which is the active form 
of decitabine and incorporated into DNA, where it acts 
by demethylation. Catabolizing enzymes such as cytidine 
deaminase (CDA) can catalyze decitabine metabolites 
to uridine and deoxyuridine, therefore decreasing the 
amount of 5-aza-dCTP that can be formed.
In solid tumors such as pancreatic ductal adenocarci-
noma, hENT1 expression was used to identify subgroups 
of patients with different disease progression risk, while 
DCK expression was shown to be most relevant to mor-
tality risk [7]. In cancer cell lines, those most resistant to 
decitabine had a combination of low expression of DCK, 
hENT1 and high CDA expression [8]. Furthermore, 
a high CDA/DCK ratio has been reported to predict 
response to decitabine [9]. A recent study by Wu et  al. 
[10] showed that high hENT1 expression is a predictor 
for response to decitabine in MDS. However, the samples 
involved in their study were insufficiently large, and the 
effect of hENT1 expression on patient survival was not 
addressed. Furthermore, to our knowledge, no in  vitro 
studies have shown the direct effect of hENT1 expression 
on the demethylation of decitabine in MDS cells.
Here, we enrolled a total of 98 patients treated with 
decitabine to further determine whether hENT1, hENT2, 
DCK, and CDA can affect the response and prognosis in 
MDS patients treated with decitabine. We also investigated 
the alteration of hypomethylation and the subsequent bio-
logical actions induced by decitabine in the SKM-1 cell 
line following knockdown of hENT1 expression.
Methods
Patients
All patients enrolled in this study had been diagnosed 
with MDS at our department according to French–
American–British (FAB)/World Health Organization 
(WHO) classification criteria [11, 12]. Bone marrow 
(BM) samples were obtained at diagnosis of MDS before 
the initiation of any treatment between September 2009 
and December 2013 following approval by the local eth-
ics committee and according to institutional guidelines. 
Each of the 98 MDS patients treated with decitabine pro-
vided written informed consent. The characteristics of 
the MDS patients are listed in Table 1. As of December 
2014, the median follow-up period was 24 months (range 
2–62  months). This study was approved by the Ethics 
Committee of Shanghai Jiao Tong University Affiliated 
Sixth People’s Hospital.
Real‑time quantitative polymerase chain reaction
Total RNA was extracted from 2  ml of BM mono-
nuclear cells (BMNCs) using the RNeasy Mini Kit 
(QIAGEN, Hilden, Germany) according to the manufac-
turer’s instructions. cDNA was synthesized by random 
priming from 10  µL of total RNA using the RevertAid™ 
First Strand cDNA Synthesis Kit (Fermentas, Burling-
ton, Canada) according to the manufacturer’s instruc-
tions. PCR was performed in a fluorescent quantitation 
PCR cycler (LightCycler, Roche, Switzerland) in a final 
volume of 10 μL, including 1 µL of cDNA, 0.5 μM of each 
primer, 4  mM MgCl2, and 2  μL of the supplied enzyme 
mix containing the reaction buffer, FastStart Taq DNA 
polymerase, and DNA double-strand-specific SYBR 
Green I dye for PCR product detection. Primer sequences 
were as follows: hENT1 (NM_001078177.1): 5′-TC 
TCCAACTCTCAGCCCACCAA-3′ (sense) and 5′-CC 
TGCGATGCTGGACTTGACCT-3′ (antisense); hENT2 
(NM_001532.2): 5′-ACCATGCCCTCCACCTACAG-3′ 
(sense), 5′-GGGCCTGGGATGATTTATTG-3′ (antisense); 
DCK (NM_000788.2): 5′-GGCCGCCACAAGACTAAGG 
A-3′ (sense) and  5′-CACCATCTGGCAACAGGTTCA-3′ 
(antisense); and CDA (NM_001785.2): 5′-CCTGCAGGC 
AAGTCATGAGAG-3′ (sense); 5′-ACCATCCGGCTTGGTC 
ATGTA-3′ (antisense). The primer sequences for GAPDH 
were as follows: 5′-GCACCGTCAAGGCTGAGAAC-3′ 
(sense) and 5′-GTGGTGAAGACGCCAGTGGA-3′ (anti-
sense). PCR conditions were as follows: preincubation at 
95  °C for 30 s, then 40 cycles of 95  °C for 15 s, 62  °C for 
30 s, and 72 °C for 30 s. The threshold cycle (Ct) value was 
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subsequently determined, and the relative quantification of 
mRNA expression was calculated using the comparative Ct 
method.
The relative quantification value of the target, which was 
normalized to that of an endogenous control (GAPDH) 
and relative to that of a calibrator (the mean expression 
level of normal controls), was expressed as 2−ΔΔCt (fold 
difference) where ΔCt =  Ct of the target gene-Ct of the 
endogenous control gene (GAPDH) and ΔΔCt = ΔCt of 
the samples for the target gene −ΔCt of the calibrator for 
the target gene [13]. To analyze the characteristics of tar-
get gene expression levels in MDS treated with decitabine, 
the mean expression level of target genes in BM from 20 
normal donors (median age, 60  years; male: female 2:1) 
was used as a control. Based on control mean expression 
levels of each gene, we divided the enrolled patients into 
two groups: a high gene expression group with 2−ΔΔCt val-
ues above mean levels, and a low gene expression group 
with 2−ΔΔCt values below mean levels.
Decitabine treatment
All patients were treated with decitabine (Johnson and 
Johnson Inc., New Brunswick, NJ), which was adminis-
tered at a dose of 20  mg/m2 by continuous intravenous 
infusion for 1 h, and repeated daily for 5 days. The cycle 
was repeated every 4 weeks, depending on each patient’s 
recovery from myelosuppression. BM examinations 
were performed 4 weeks after decitabine treatment was 
completed to evaluate the response. The final treatment 
response was assessed after at least four cycles of decit-
abine therapy, except for patients who discontinued ther-
apy because of disease progression when receiving fewer 
than four cycles of therapy.
Responses to decitabine therapy and overall survival
The primary observation parameter was the overall 
response rate (OR), which included the rates of com-
plete remission (CR), marrow CR (mCR), hematologic 
improvements (HI), and cytogenetic CR (CCR) (only in 
patients with abnormal karyotypes before therapy). The 
treatment response was assessed using modified Interna-
tional Working Group (IWG 2006) response criteria [14]. 
Overall survival (OS) was calculated from the initial date 
of decitabine treatment to the date of death from any 
cause.
Cell line and culture
Decitabine was purchased from Sigma-Aldrich (St Louis, 
MO), dissolved in dimethyl sulfoxide (DMSO; Sigma-
Aldrich) at 10  mM, and stored at −20  °C. SKM-1 cells 
(Health Science Research Resources Bank, Osaka, Japan) 
were grown in RPMI-1640 medium (Gibco, Grand 
Island, NY) containing 10 % heat-inactivated fetal bovine 
serum, 100  IU/ml penicillin, and 100  µg/ml strepto-
mycin in a humidified atmosphere of 5 % CO2 at 37  °C. 
Cells were seeded in 12-well plates at a density of 5 × 105 
cells in 2 ml culture medium and treated with DMSO or 
decitabine every 24 h. After 24, 48, and 72 h, cells were 
harvested and DNA was isolated using DNA reagent 
(QIAGEN, Hilden, Germany) according to the manu-
facturer’s instructions. As a solvent control, DMSO was 
added to a final concentration of 0.01 %.
Lentivirus‑delivered small interfering (si)RNA gene 
knockdown
The siRNA sequence for hENT1 knockdown was 
5′- ACCAATGAAAGCCACTCTA-3′, and the scram-
bled control siRNA sequence was 5′-TTCTCCGAACG 
TGTCACGT-3′. The siRNA sequences were cloned 
into the pLSLG lentiviral vector. This and the help vec-
tor (pLV-HELP) were transfected into 293FT cells for 
viral packaging. Virus was then collected for the infec-
tion of SKM-1 cells in the presence of 5 μg/ml polybrene 
Table 1 Characteristics of  the 98 MDS patients treated 
with decitabine
MDS myelodysplastic syndrome, FAB French-American-British, WHO world 
health organization, RCMD refractory cytopenia with multilineage dysplasia, RAS 
refractory anemia with ringed sideroblasts, RAEB refractory anemia with excess 
of blasts, RAEB-t refractory anemia with excess of blasts in transformation, CMML 
chronic myelomonocytic leukemia
Characteristics Category
Median age (range) 62 (20–82)
Sex, n (%)
 Male 69 (70)
 Female 29 (30)
WHO/FAB classification, n (%)
 RCMD 19 (20)
 RAS 2 (3)
 RAEB-1 25 (22)
 RAEB-2 29 (30)
 RAEB-t 14 (17)
 CMML 9 (8)
Karyotypes, n(%)
 Normal 49 (50)
 +8 7 (7)
 −7/7q- 9 (9)
 −5/5q- 2 (2)
 20q- 5 (5)
 Complex 13 (13)
 Others 13 (13)
International prognostic scoring system, n (%)
 Low 4 (4)
 Intermediate-1 33 (34)
 Intermediate-2 34 (35)
 High 27 (27)
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(Genechem, Shanghai, China). After 4  days of culture, 
cells were used for further experiments.
Pyrosequencing to measure LINE‑1 methylation
Genomic DNA was extracted using DNeasy Blood & 
Tissue Kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions and then modified by treat-
ment with sodium bisulfite using the Zymo EZ DNA 
Methylation kit (Zymo Research, Irvine, CA) follow-
ing the manufacturer’s protocol. A modified method of 
PCR-based pyrosequencing was performed to quantify 
methylation of LINE-1 repetitive elements, as previously 
described [15]. The primers used in PCR were: forward 
primer (5′-TTTTTTGAGTTAGGTGTGGGATA-3′) 
and biotinylated reverse primer (Biotin-AAAAATC 
AAAAAATTCCCTTTCC-3′). PCR cycling conditions 
were: 45 cycles of 95 °C for 15 s, 50 °C for 20 s, and 72 °C 
for 30  s. The PCR product was bound to streptavidin 
Sepharose beads (Amersham Biosciences, Uppsala, Swe-
den) and then purified. The LINE-1-S3 pyrosequencing 
primer (5′-GGGTGGGAGTGAT-3′) was annealed to 
the purified single-stranded PCR product. Pyrosequenc-
ing was performed using the PSQ HS 96 Pyrosequencing 
System. The average relative amount of cytosine in the 
three CpG sites was used as the overall LINE-1 methyla-
tion level.
Statistical methods
Statistical analyses were performed using the Statistical 
Package for Social Sciences (SPSS 16.0; SPSS Inc., Chi-
cago, IL). Two independent sample populations were 
compared using the Student’s t test. The Pearson χ2 or 
Fisher’s exact test was applied to compare the enumera-
tion data between groups. The Kaplan–Meier method 
was used to estimate median OS. The log-rank test 
was used to compare Kaplan–Meier survival estimates 
between groups. Multivariate Cox proportional hazards 
models were used to calculate the hazard ratios and 95 % 
confidence intervals of the associations between risk fac-




A total of 98 patients were enrolled in this study. The 
median patient age was 62  years (range 20–82  years), 
and the male to female ratio was 2.38:1 (69:29). All 
patients in this study were diagnosed with de novo 
MDS. The FAB/WHO disease sub-types at study entry 
were refractory cytopenia with multilineage dysplasia 
(RCMD; n  =  19), refractory anemia with ringed side-
roblasts (RAS; n  =  2), refractory anemia with excess 
blasts (RAEB-1; n = 25 and RAEB-2; n = 29), refractory 
anemia with excess blasts in transformation (RAEB-
t; n  =  14), and chronic myelomonocytic leukemia 
(CMML) (n = 9). The International Prognostic Scoring 
System (IPSS) [16] risk category was low in four, inter-
mediate (INT)-1 in 33, INT-2 in 34, and high risk in 27 
patients. A total of 49 patients (50.0 %) with abnormal 
karyotypes were determined by G-binding analysis [17]. 
Patient characteristics are listed in Table 1. The median 
number of decitabine therapy cycles was four (range 
2–10). Eight patients discontinued treatment after two 
cycles of decitabine therapy because of disease progres-
sion. All patients were evaluable.
HENT1 expression levels were significantly elevated 
in responders to decitabine therapy
Among the 98 MDS patients, 67 (68.4  %) achieved a 
response, including 33 (33.7  %) with CR, 11 (11.2  %) 
with mCR only, 15 (15.3  %) with HI only, and eight 
(8.2  %) with mCR with HI. Thirty-one (31.6  %) 
patients showed no response to decitabine therapy. 
Among the 49 patients with abnormal karyotypes, 15 
(30.6  %) reached CCR. Patients responding to decit-
abine showed significantly increased mean hENT1 
expression levels compared with non-responders 
(1.79  ±  1.53-fold vs 0.94  ±  0.77-fold, p  =  0.004) 
(Fig.  1a). Patients who achieved CR with decitabine 
also showed increased hENT1 expression levels com-
pared with those who did not achieve CR (2.05 ± 1.86-
fold vs 1.25 ± 1.00-fold, p = 0.007) (Fig. 1b). Increased 
hENT1 expression was also detected in patients who 
achieved CCR when compared with those who did 
not (2.97  ±  1.87-fold vs 1.16  ±  1.05-fold, p  <  0.001) 
(Fig.  1c). HENT1 expression level also increased in 
patients achieved mCR or HI when compared to that 
in NR patients (Additional file  1). Expression levels 
of hENT2, DCK, and CDA did not affect response 
including (OR, CR, CCR, mCR or HI) rate in MDS 
patients treated with decitabine (Fig. 1a–c; Additional 
file 1a, b).
High expression of hENT1 confers response to decitabine 
therapy
The mean expression level of hENT1, hENT2, DCK, and 
CDA of 20 normal donors was used as a control. Com-
pared with these, a total of 63 patients (64.3 %) showed 
high hENT1 expression and 35 (35.7  %) showed low 
hENT1 expression. Among the 63 high hENT1 expres-
sion patients, 50 (79.4 %) achieved a response, which was 
a significantly higher proportion than the 17/35 (48.6 %) 
low hENT1 expression patients (p =  0.004). Twenty-six 
of 63 (41.3 %) hENT1 high expression patients achieved 
CR, which was significantly higher than that of low 
hENT1 expression patients (7/35, 20.0  %) (p  =  0.033). 
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There was no difference in mCR or HI rate between the 
high and low hENT1 expression groups.
Among the 49 patients with abnormal karyotype, the 
CCR rate was significantly higher in the hENT1 high 
expression group (14/32, 43.8  %) than the low hENT1 
expression group (1/17, 5.9 %) (p = 0.006) (Fig. 2a). There 
was no significant difference in OR, CR, CCR, mCR, or 
HI between patients with high and low hENT2 expres-
sion (Fig. 2b), high and low DCK (Fig. 2c), high and low 
CDA (Fig. 2d), or between the high and low CDA/DCK 
ratio (Fig. 2e).
Fewer treatment cycles were needed for patients with high 
hENT1 expression to achieve CR
We recorded the number of cycles needed for patients 
treated with decitabine to achieve CR. The median num-
ber of administered cycles was three (range 1–4) for all 
patients who achieved CR. For patients with high hENT1 
expression levels, significantly fewer cycles (median, two 
(range 1–4) cycles) were needed to achieve CR compared 
with low hENT1 expression patients (median, three 
(range 2–4) cycles) (p = 0.035).
High hENT1 expression predicted prolonged survival 
in higher‑risk MDS patients receiving decitabine treatment
During a median follow-up period of 24.0  months 
(range 2–62  months), the median OS of 98 patients 
was 18.0  months [95  % confidence interval (CI): 14.8–
21.1  months]. The median OS between all MDS patients 
with high and low hENT1 expression was not significantly 
different (23.0 vs 17.0 months; p = 0.207) (Fig. 3a). How-
ever, among the 61 higher-risk (IPSS int-2 or high-risk) 
patients, the median OS of patients with high hENT1 
expression was significantly longer than that of low hENT1 
expression patients (22.0 vs 14.0  months; p  =  0.027) 
(Fig. 3b). Univariate analysis showed hENT1 was a progno-
sis predictor in higher risk MDS patients treated with decit-
abine (p = 0.027). Furthermore, multivariate Cox analyses 
were conducted by integrating several risk factors includ-
ing hemoglobin, platelet, BM blast, hENT1 expression level. 
In the multivariate analyses, low hENT1 [hazard ration 
(HR) = 2.363; 95 % confidence interval (CI) = 1.174–4.757; 
Likelihood ratio test, p = 0.031] appeared to be independ-
ent prognostic markers of adverse events in higher risk 
MDS treated with decitabine (Table 2).
Lower expression of hENT1 in SKM‑1 cells reduces the 
demethylation effect of decitabine
HENT1 mRNA expression levels were significantly 
decreased in hENT1-siRNA-lentivirus-transfected SKM-1 
cells compared with control lentivirus-transfected SKM-1 
cells (Fig.  4a). Before decitabine treatment, the LINE-1 
methylation status did not differ significantly between 
hENT1-knockdown and control cells. However, after 
decitabine treatment (at final concentrations of 0.5, 1.0, 
and 5.0 µmol/l), LINE-1 methylation levels were lowered 
in both hENT1-knockdown and control cells. The low-
est methylation status was achieved following treatment 
Fig. 1 Comparison of hENT1, hENT2, DCK, and CDA expression levels 
between responders and non-responders; CR and non-CR; CCR 
and non-CCR. a Increased hENT1 in responders compared to non-
responders. hENT2, DCK, and CDA mRNA expression levels did not 
differ between responders and non-responders. b Elevated hENT1 
level in CR patients compared to non-CR patients. No significant dif-
ference of hENT2, DCK, and CDA mRNA level between CR and non-CR 
patients. c Increased hENT1 rather than hENT2, DCK, or CDA level in 
CCR patients compared to non-CCR patients
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with 1.0  µmol/l decitabine in both groups of cells. How-
ever, compared with the control group, the demethylation 
effect of decitabine was significantly weakened in hENT1-
knockdown SKM-1 cells (p = 0.0026) (Fig. 4b–f). The big-
gest gap of demethylation effect between the two groups 
was observed at a decitabine treatment of 0.5 µmol/l.
Discussion
Mechanisms of in  vivo resistance to nucleoside analogs 
are complex and remain unresolved. One possibility 
may result from the presence of insufficient intracellular 
triphosphate, as seen for some nucleic acid analogs such 
as cytarabine and fludarabine [18].
Decitabine is administered to patients without knowl-
edge of their genetic background, which may affect drug 
efficacy. The primary mechanism for insufficient intra-
cellular concentrations of decitabine may result from a 
combination of multiple factors including inadequate 
uptake through membrane transporters, DCK deficiency, 
increased CDA, or high dNTP pools. HENT1 is the 
major membrane transporter for decitabine transporting 
into cell, which can affect the intracellular drug concen-
tration and thus the efficacy of decitabine [19]. Studies 
both in cancer cell lines [8] and in MDS patients [9, 10] 
showed that resistant to decitabine had a low hENT1. In 
accordance with these findings, our results revealed sig-
nificantly higher hENT1 expression levels in decitabine 
responders compared with non-responders. Moreover, 
in CR patients, even higher hENT1 levels were observed 
compared with non-CR patients. In patients with high 
hENT1 expression, significantly higher response rate 
and CR rate was observed, compared with those of low 
hENT1 expression patients. Therefore, high hENT1 
expression predicts response to decitabine in MDS 
patients and a higher possibility to achieve CR.
For MDS patients with abnormal karyotypes, CCR 
means the deeper remission and prolonged relapse-free 
survival [20]. To our best knowledge, there is no effect 
indictor for predicting CCR in MDS patients received 
decitabine therapy. Of note, in the current study, results 
showed that patients achieved CCR had a significantly 
higher hENT1 expression, compared with non-CCR 
cases (2.97 ±  1.87-fold vs 1.16 ±  1.05-fold, p  <  0.001). 
Among the 15 CCR patients, 14 presented with high 
hENT1 expression, and only one showed low hENT1 lev-
els. Therefore, a high hENT1 level is a critical factor to 
achieve CCR for MDS patients treated with decitabine.
A high CDA or CDA/DCK ratio has previously been 
reported to contribute to decreased cytidine analog half-life 
and likely contributes to worse outcomes with decitabine 
therapy [9, 21]. However, in our study, this ratio did not dif-
fer significantly between responders and non-responders. 
It is conceivable that this discrepancy reflects differences in 
drug metabolism among diverse racial groups.
Unlike traditional cytotoxic therapies that induce rapid 
responses in MDS (mostly after one or two cycles) [22, 
Fig. 2 Comparison of response rate in patients treated with decitabine between those with a high and low hENT1 expression, b high and low 
hENT2 expression, c high and low DCK expression, d high and low CDA expression, and e high and low CDA/DCK ratio
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23], decitabine has a different pattern, in which a response 
is rare after one cycle but improves over time [4, 24]. Our 
results showed that patients with higher hENT1 expression 
achieved CR with fewer cycles of therapy than those with 
lower hENT1 expression. We speculate that higher hENT1 
levels can result in higher intracellular concentrations for 
one dose, a subsequently improved drug efficacy for each 
cycle, and therefore fewer cycles to reach the best response.
The results also showed that high expression of hENT1 
predicted a prolonged survival in higher-risk MDS 
patients receiving decitabine treatment. Multivariate 
regression analysis confirmed that the hENT1 expression 
level was an independent prognostic indicator in higher 
risk MDS patients treated with decitabine, regardless of 
BM blast percentage, platelet count or hemoglobin level. 
The prolonged survival in patients with high hENT1 
expression may result from a better response compared 
with patients with low hENT1. Therefore, besides the 
prognosis predicting system such as IPSS/IPSS-Revision 
(IPSS-R) [25]/WHO prognostic scoring system (WPSS) 
[26], hENT1 expression level could serve as a com-
plementary prognosis predictor for higher-risk MDS 
patients treated with decitabine.
The in  vitro study showed that knockdown of hENT1 
weakened the hypomethylation effect of decitabine treat-
ment in an MDS cell line. Moreover, the biggest gap in 
the demethylation effect between the two groups was 
at a decitabine treatment concentration of 0.5  µmol/l, 
while the effect tended to close in the control group with 
increasing decitabine concentrations. Therefore, hENT1 
expression levels appear to affect the decitabine efficacy 
at low concentrations. Increasing decitabine to a final 
concentration of 5 µM resulted in no difference between 
the hENT1-knockdown group and controls. Therefore, 
for MDS patients with low hENT1 expression, increasing 
the dosage of decitabine may be a good choice to achieve 
a clinical response. Drugs targeting to increase expres-
sion of hENT1 may reduce the primary resistance to 
decitabine and increase the response rate. Notably, other 
genes involved in the transcriptional down-regulation of 
hENT1 expression may also affect the response to decit-
abine. The hENT1 promoter region contains consensus 
sequences for several transcription factors, including the 
C/EBP homologous protein (CHOP), a member of the 
CCAAT/enhancer binding protein family [27, 28]. The 
CHOP may transcriptional regulate the expression of 
hENT1 and thus affect the response to decitabine, which 
will be evaluated in our later study.
Nevertheless, the hENT1 expression level is not the 
only factor that can predict response to decitabine. The 
expression of multidrug resistant protein 1 (MRP1) [29] 
may result to resistance to decitabine in MDS patients, 
which may partly account for the no response of the 
drug. Other factors including cytogenetic changes (mon-
osomy 7 or complex karyotypes) [4, 20], and mutations 
in genes such as TET2 [30] and DNMT3a [31], have 
also been documented. In the future, analysis of hENT1 
expression combined with other factors can serve as an 
effective response prediction system for decitabine ther-
apy in MDS, which will benefit more patients.
Conclusions
In summary, high expression of hENT1 predicts a good 
response to decitabine and prolonged survival in higher-
risk MDS patients treated with decitabine. Knockdown 
of hENT1 expression weakens the demethylation effect of 
decitabine. The hENT1 expression level could serve as an 
Fig. 3 Comparison of overall survival of patients with high and low 
hENT1 expression treated with decitabine. a In all MDS patients, the 
median overall survival time was not significantly different between 
high hENT1 patients and low hENT1 patients. b In the higher-risk 
patients, a prolonged overall survival time was observed in patients 
with high hENT1 compared to those with low hENT1
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effective response predictor in MDS patients treated with 
decitabine.
Additional file
Additional file 1. HENT1 expression level increased significantly in 
patients achieved mCR (a) or HI (b) when compared to that in NR patients, 
while expression levels of hENT2, DCK, and CDA was not significantly dif-
ferent between mCR (a) or HI (b) patients and NR.
Abbreviations
CCR: cytogenetic complete response; CDA: cytidine deaminase; CMML: 
chronic myelomonocytic leukemia; CR: complete response; DCK: deoxycy-
tidine kinase; FAB: French–American–British; hENT1: human equilibrative 
nucleoside transporter 1; IPSS: international Prognostic Scoring System; LINE1: 
long interspersed nucleotide elements 1; MDS: myelodysplastic syndrome; OR: 
overall response; Q-PCR: quantitative real-time PCR; RAEB-1: refractory anemia 
with excess blasts-1; RAEB-2: refractory anemia with excess blasts-2; RAEB-t: 
refractory anemia with excess of blasts in transformation; RAS: refractory ane-
mia with ringed sideroblasts; RCMD: refractory cytopenia with multilineage 
dysplasia; WHO: World Health Organization.
Table 2 Univariate and Multivariate analysis for survival in higher risk MDS patients treated with decitabine
Criterion Univariate P value Multivariate P value HR 95.0 % CI for HR
Hemoglobin (>80 g/L vs ≤80 g/L) 0.010 0.026 2.023 1.177–4.112
Platelet (>50 × 109/L vs ≤50 × 109/L) 0.008 0.022 2.134 1.113–4.091
Bone marrow blasts percentage (5–10/10–20/>20 %) 0.010 0.041 1.522 1.017–2.277
hENT1 expression (high vs low) 0.027 0.031 2.363 1.174–4.757
Age (>60 years vs ≤60 years) 0.796 – – –
Gender (male vs female) 0.569 – – –
Neutrophils (>1.0 × 109/L vs ≤1.0 × 109/L) 0.212 – – –
Karyotype (low/intermediate/high) 0.318 – – –
hENT2 expression (high vs low) 0.201 – – –
DCK expression (high vs low) 0.203 – – –
CDA expression (high vs low) 0.411 – – –
Fig. 4 LINE-1 methylation level before and after decitabine treatment in hENT1-siRNA and control SKM-1 cells. a hENT1 mRNA expression in SKM-1 
cells transfected with hENT1-siRNA-lentivirus and control lentivirus. b LINE-1 methylation levels changed with different concentrations of decit-
abine. c–f A pyrosequencing assay was used to measure LINE-1 methylation before decitabine treatment in control lentivirus-transfected (c) and 
hENT1-siRNA cells (d). LINE-1 methylation was also measured after 1 µM decitabine treatment in control (e) and hENT1-siRNA cells (f)
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